American Society of Clinical Oncology 2013

The American Society of Clinical Oncology (ASCO) is holding its 2013 Annual Meeting in Chicago, IL from May 31-June 4, 2013. "Building Bridges to Conquer Cancer" is the theme of this year's meeting which will bring more than 250,000 oncology professionals together.

Coverage

Dr. George Addresses Provider Issues Regarding Immunotherapies
   |    ASCO 2013
Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, specifically discusses the immunotherapy agent, sipuleucel-T (Provenge) used in the treatment of prostate cancer.
   |    ASCO 2013
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting.
   |    ASCO 2013
Ongoing shortages of common oncology chemotherapies have compelled physicians to substitute more expensive drugs, delay or suspend clinical trials, or even skip doses of chemotherapy, according to survey results gathered by a team from the University of Pennsylvania.
   |    ASCO 2013
Two-thirds of the metastatic myeloma patients in a phase II study were still alive a year after receiving a new combination therapy, compared to slightly more than half of patients receiving a standard monotherapy for the cancer, according to results presented today at the 49th Annual meeting of the American Society of Clinical Oncology in Chicago.
   |    ASCO 2013
Ovarian cancer survivors could have an option for treatment after chemotherapy, based on the outcome of a phase III study of an approved oral therapy for kidney cancer and soft tissue sarcoma.
   |    ASCO 2013
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that in regard to payers impacting the use of immunotherapies, most payers have decided they will respect the judgment of the Food and Drug Administration, Centers for Medicare & Medicaid Services and the National Comprehensive Cancer Network.
   |    ASCO 2013
In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013.
   |    ASCO 2013
An ongoing phase I study of patients who have experienced relapsed and/or refractory multiple myeloma has found that this population was largely able to tolerate a new oral 20S proteasome inhibitor after receiving other prior treatments.
Feature
$vacMongoViewPlus$